Nuvalent(NUVL.US) Officer Sells US$377.7K in Common Stock
$Nuvalent(NUVL.US)$ Officer Noci Darlene sold 5,000 shares of common stock on Jul 1, 2024 at an average price of $75.54 for a total value of $377.7K.Source: Announcement What is statement of changes i
Nuvalent(NUVL.US) Officer Sells US$754.34K in Common Stock
$Nuvalent(NUVL.US)$ Officer Balcom Alexandra sold 10,000 shares of common stock on Jun 28, 2024 at an average price of $75.43 for a total value of $754.34K.Source: Announcement What is statement of ch
Nuvalent(NUVL.US) Director Sells US$160.44K in Common Stock
$Nuvalent(NUVL.US)$ Director Shair Matthew sold 2,000 shares of common stock on Jun 24, 2024 at an average price of $80.22 for a total value of $160.44K.Source: Announcement What is statement of chang
Nuvalent(NUVL.US) Director Sells US$387.78K in Common Stock
$Nuvalent(NUVL.US)$ Director Conley Emily sold 5,000 shares of common stock on Jun 14, 2024 at an average price of $77.56 for a total value of $387.78K.Source: Announcement What is statement of change
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transf
Nuvalent(NUVL.US) Officer Sells US$643.21K in Common Stock
$Nuvalent(NUVL.US)$ Officer Miller Deborah Ann sold 8,000 shares of common stock on Jun 6, 2024 at an average price of $80.4 for a total value of $643.21K.Source: Announcement What is statement of cha
Nuvalent Insider Sold Shares Worth $643,213, According to a Recent SEC Filing
Deborah Ann Miller, Chief Legal Officer, on June 06, 2024, sold 8,000 shares in Nuvalent (NUVL) for $643,213. Following the Form 4 filing with the SEC, Miller has control over a total of 33,300 shares
Nuvalent(NUVL.US) Director Sells US$134.44K in Common Stock
$Nuvalent(NUVL.US)$ Director Shair Matthew sold 2,000 shares of common stock on May 28, 2024 at an average price of $67.22 for a total value of $134.44K.Source: Announcement What is statement of chang
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...
Nuvalent(NUVL.US) Director Sells US$345.45K in Common Stock
$Nuvalent(NUVL.US)$ Director Conley Emily sold 5,000 shares of common stock on May 15, 2024 at an average price of $69.09 for a total value of $345.45K.Source: Announcement What is statement of change
Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing
Emily Conley, Director, on May 15, 2024, sold 5,000 shares in Nuvalent (NUVL) for $345,450. Following the Form 4 filing with the SEC, Conley has control over a total of 8 shares of the company, with 8
Wedbush Reiterates Outperform on Nuvalent, Maintains $99 Price Target
Wedbush analyst David Nierengarten reiterates Nuvalent with a Outperform and maintains $99 price target.
Nuvalent Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 32.85% Wedbush → $99 Reiterates Outperform → Outperform 04/17/2024 30.17% Jefferies → $97 Initi
Nuvalent Gains Breakthrough Therapy Status for Non-small Cell Lung Cancer Candidate
Nuvalent's NVL-655 Receives FDA Breakthrough Therapy Designation
Nuvalent's NVL-655 Receives FDA Breakthrough Therapy Designation
Nuvalent(NUVL.US) Director Sells US$2.47 Million in Common Stock
$Nuvalent(NUVL.US)$ Director Shair Matthew sold 37,500 shares of common stock on May 13, 2024 at an average price of $65.84 for a total value of $2.47 million.Source: Announcement What is statement of
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Nuvalent (NUVL) Gets a Buy From Stifel Nicolaus
Nuvalent's Promising Clinical Progress and Financial Stability Support Strong Buy Rating
Nuvalent Q1 Net Loss Widens
Nuvalent (NUVL) reported a Q1 net loss Thursday of $0.69 per diluted share, widening from a loss of $0.44 a year earlier. Analysts surveyed by Capital IQ expected a loss of $0.67 per share. The clinic